Robert L. van Nostrand is Director at Intra-Cellular Therapies, Inc. (ITCI). They have made 4 open-market trades across 3 companies since 2012, most recently 2026-01-07.
CIK 0001225198
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $36K since 2012, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SLS | BUY | 2025-06-12 | 2025-06-13 | $1.48 | $15K | +18.7% | +15.8% | +10.5% |
| ITCI | SELL · 10b5-1 | 2024-06-18 | 2024-06-21 | $75.91 | $3.0M | -9.8% | -0.1% | +0.5% |
| ITCI | SELL | 2024-02-27 | 2024-02-28 | $72.93 | $2.9M | -8.6% | -4.6% | -8.3% |
| ITCI | SELL · 10b5-1 | 2023-04-17 | 2023-04-19 | $63.00 | $630K | +1.0% | -0.2% | +0.5% |
| ITCI | SELL | 2022-08-11 | 2022-08-12 | $57.13 | $1.7M | -5.3% | +0.1% | -4.6% |
| MBLX | BUY | 2012-11-30 | 2012-12-04 | $1.07 | $21K | -12.8% | -0.7% | -0.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.